Valuation: EnteroMedics Inc

Market Cap 14.84M 12.9M 12.01M 11.03M 20.82M 1.42B 21.15M 142M 55.56M 705M 55.75M 54.52M 2.37B P/E 2026 *
-3x
P/E 2027 * -2.31x
Enterprise Value 14.84M 12.9M 12.01M 11.03M 20.82M 1.42B 21.15M 142M 55.56M 705M 55.75M 54.52M 2.37B EV / Sales 2026 *
99x
EV / Sales 2027 * 59.4x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 130K 121K 111K 210K 14.32M 214K 1.43M 561K 7.13M 563K 551K 23.9M 250K 217K 202K 186K 351K 23.87M 356K 2.38M 936K 11.88M 939K 918K 39.84M
Net income -4.89M -4.25M -3.96M -3.63M -6.86M -467M -6.97M -46.64M -18.3M -232M -18.36M -17.96M -779M -7.77M -6.75M -6.29M -5.77M -10.9M -742M -11.07M -74.1M -29.08M -369M -29.18M -28.54M -1.24B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-